Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a range of new probes for in situ hybridization, a technique used in pathology laboratories to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results